Low risk — use of or exposure to this product is not likely to cause adverse health consequences.
Guaifenesin and Codeine Phosphate Oral Solution USP Recalled by PAI Holdings, LLC. dba Pharmaceutical Associates Inc Due to Superpotent; sodium benzoate preservative
What You Should Do
Stop using this product immediately. Do not consume, use, or distribute it.
Return the product to the place of purchase for a full refund. If you have questions, contact PAI Holdings, LLC. dba Pharmaceutical Associates Inc directly.
Affected Products
Guaifenesin and Codeine Phosphate Oral Solution USP, 100mg/10 mg per 5 mL, 16 fl oz (473 ml) bottles, PAI Pharmaceutical Associates, Inc., Greenville, SC 29605, NDC 0121-0775-16
Quantity: 4080 Bottles
Why Was This Recalled?
Superpotent; sodium benzoate preservative
Where Was This Sold?
This product was distributed to 1 state: OH
About PAI Holdings, LLC. dba Pharmaceutical Associates Inc
PAI Holdings, LLC. dba Pharmaceutical Associates Inc has 7 total recalls tracked by RecallDetector.
Related Recalls
Icosapent Ethyl Capsules Recalled by Zydus Pharmaceuticals (USA) Inc Due to Failed Tablet/Capsule specifications: Red dots inside capsule and...
Zydus Pharmaceuticals (USA) Inc · March 9, 2026
Product label: Temozolomide Capsules Recalled by Rising Pharma Holding, Inc. Due to Failed Impurities/Degradation Specifications: An out-of-specification result observed during...
Rising Pharma Holding, Inc. · March 3, 2026
Semaglutide Inj. Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Tirzepatide Inj Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Tirzepatide Inj Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Data sourced from the FDA (Drug). Last updated March 26, 2026. View original report